$RKLB

Kampani Arjun sold $14.2M of RKLB

Kampani Arjun (SVP & General Counsel) sold 98,668 shares of Rocket Lab Corp (RKLB) at an average of $144.38 ($139.41–$150.00, $14.25M total) across 8 trades over 2026-05-26 to 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kampani Arjun
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RKLB
Neutral
medium confidence
Mentioned
$RKLB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RKLBNeutralLow
01

Why it matters

The disclosure provides a concrete, time-stamped insider selling event (open-market sale) and the approximate dollar value, but it does not include new operational or financial guidance.

02

Market read

For RKLB, the only new tradable input is the insider sale size and timing; it is unlikely to change the fundamental thesis by itself.

03

What to watch

Traders may over-weight insider sales; the key nuance here is that the plan is pre-arranged, and the trades occurred days before the filing date.

Relevance 6/10Novelty 4/10Timing: filed 2026-05-28, covering sales on 2026-05-26 to 2026-05-27

Background

This is an SEC Form 4 insider transaction disclosure for Rocket Lab Corp, reported by SVP and General Counsel Kampani Arjun.

Company-level read

Ticker impact

$RKLBNeutralMedium confidence
Context

Rocket Lab Form 4 shows SVP and General Counsel Kampani Arjun sold 98,668 shares in open-market trades totaling about $14.25M.

Expected impact

Likely limited, short-lived impact unless paired with other company-specific catalysts.

Evidence & confidence

The filing is a primary-source Form 4 and the sale size is material, but the presence of a pre-arranged 10b5-1 plan reduces interpretive signal about near-term business outlook.

Market effects

Minimal direct read-through to the space/launch sector from a single 10b5-1 insider sale.

None.

None.

Counterpoint

The sale could be purely liquidity-driven under the 10b5-1 plan, implying no actionable bearish signal for RKLB fundamentals.

Key entities

  • Rocket Lab Corp

    Subject of the Form 4 insider transaction disclosure.

  • Kampani Arjun

    SVP and General Counsel who executed the open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RKLBHigh

Rocket Lab (RKLB) Stock Drops After Neutron Rocket Launch Delay

Rocket Lab (RKLB) shares fell 7.9% during trading and 7.3% after-hours after delaying its Neutron rocket launch to 2027 due to manufacturing issues. The company's P/S ratio is 45.17, above historical and industry averages, reflecting high growth expectations. Insider selling totaled $683.3 million over the past year. Rocket Lab has a GF Score of 77/100, indicating strong financial health but weak profitability.

$RKLBMed

Rocket Lab pushes Neutron rocket's debut flight to 2027, shares fall

Rocket Lab announced a delay in the debut flight of its Neutron rocket to 2027, pushing back from the previously targeted fourth quarter of 2026. The news caused the company's shares to drop about 6% in extended trading. Neutron is a reusable medium-lift rocket aimed at competing for larger commercial and national-security missions. Recently, Rocket Lab secured a multi-year launch agreement for 20 missions with Tokyo-based Synspective.

$RKLBHigh

Why is Rocket Lab stock tumbling today?

Rocket Lab (RKLB) stock dropped 7.2% in after-hours trading after delaying its Neutron rocket launch to 2027 due to manufacturing issues. The company also faces insider-selling pressure and a challenging macro environment with rising Fed rate hike bets. The stock is down over 60% from its 52-week high.

$RKLBHigh

Rocket Lab Stock Stumbles Despite Big Space Ambitions

Rocket Lab USA (RKLB) shares fell 8% during and after trading due to CEO Peter Beck's planned stock sale, SpaceX funding concerns, and a delay in the Neutron rocket launch to 2027. Despite record Q2 revenue of $234M and a strong backlog, investors worry about integration risks and profitability. Analysts maintain a Strong Buy rating with a $104.44 price target.